Skip to main content
Retour
NTLA logo

Intellia Therapeutics, Inc.

Qualité des données : 100%
NTLA
NASDAQ Healthcare Biotechnology
12,81 €
▼ 0,30 € (-2,29%)
Cap. Boursière : 1,51B
Fourchette du Jour
12,63 € 13,18 €
Fourchette 52 Semaines
5,90 € 28,25 €
Volume
3 336 008
Moyenne 50J / 200J
12,99 € / 12,58 €
Clôture Précédente
13,11 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E -3,7 0,3
P/B 2,3 2,9
ROE % -53,5 3,7
Net Margin % -609,9 3,8
Rev Growth 5Y % 19,6 10,0
D/E 0,1 0,2

Objectif de Cours des Analystes

Hold
19,38 € +51.3%
Low: 7,00 € High: 48,00 €
BPA Prévisionnel
-3,62 €
CA Est.
59 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 8,76 €
-1,79 € – 99,21 €
2,5 B 5
FY2029 3,86 €
-0,79 € – 43,72 €
1,6 B 10
FY2028 -0,69 €
-3,57 € – 15,82 €
670 M 12

Points Clés

Revenue grew 19,62% annually over 5 years — strong growth
Debt/Equity of 0,14 — conservative balance sheet
Negative free cash flow of -354,66M
PEG of 0,09 suggests growth is underpriced
Capital efficient — spends only 8,54% of revenue on capex

Croissance

Revenue Growth (5Y)
19,62%
Revenue (1Y)16,92%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-53,48%
ROIC-43,25%
Net Margin-609,85%
Op. Margin-651,67%

Sécurité

Debt / Equity
0,14
Current Ratio5,08
Interest Coverage0,00

Valorisation

P/E Ratio
-3,67
P/B Ratio2,25
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 16,92% Revenue Growth (3Y) 36,58%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 19,62% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 67,67M Net Income (TTM) -412,69M
ROE -53,48% ROA -49,01%
Gross Margin 76,47% Operating Margin -651,67%
Net Margin -609,85% Free Cash Flow (TTM) -354,66M
ROIC -43,25% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,14 Current Ratio 5,08
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -3,67 P/B Ratio 2,25
P/S Ratio 22,36 PEG Ratio 0,09
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 1,51B Enterprise Value 1,45B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 67,67M 57,88M 36,28M 52,12M 33,05M
Net Income -412,69M -519,02M -481,19M -474,19M -267,89M
EPS (Diluted) -3,81 -5,25 -5,42 -6,16 -3,78
Gross Profit 51,75M 47,59M 27,30M 44,55M 26,16M
Operating Income -440,99M -534,26M -515,29M -458,16M -267,85M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 842,13M 1,19B 1,30B 1,52B 1,29B
Total Liabilities 170,73M 319,06M 250,81M 284,53M 254,22M
Shareholders' Equity 671,39M 871,96M 1,05B 1,24B 1,04B
Total Debt 93,33M 210,20M 115,35M 130,70M 74,02M
Cash & Equivalents 155,46M 189,18M 226,75M 523,51M 123,41M
Current Assets 527,71M 639,86M 998,33M 1,22B 769,30M
Current Liabilities 103,88M 110,85M 115,21M 126,55M 125,83M